Puma Biotechnology, INC 8-K filings

Puma Biotechnology reported Q1 2026 results with a slight revenue decrease but raised full-year revenue and net income guidance, driven by increased demand for NERLYNX and positive interim data for alisertib.

Puma Biotechnology announced its fourth quarter and full year 2025 financial results, showing increased product revenue but a decline in Q4 net income due to tax adjustments, alongside significant debt reduction.

Puma Biotechnology reported third quarter 2025 financial results, raising its full-year NERLYNX revenue and net income estimates driven by increased U.S. demand.

Puma Biotechnology reported a significant turnaround to net income in the second quarter of 2025, driven by increased sales of its flagship cancer drug, NERLYNX.

Puma Biotechnology, Inc. has adopted Fifth Amended and Restated Bylaws to update corporate governance provisions, primarily aligning them with recent changes in Delaware law and formalizing procedures for shareholder engagement and director nominations.

Puma Biotechnology, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all eight nominated directors were elected, KPMG LLP was ratified as the independent accounting firm, and executive compensation was approved on an advisory basis.

Puma Biotechnology, Inc. announced the termination of Jeff J. Ludwig as Chief Commercial Officer, effective May 8, 2025, with his responsibilities to be absorbed by existing sales and marketing personnel.

Puma Biotechnology announces a profitable first quarter in 2025, with net income of $3.0 million, a significant improvement from the net loss in the same period last year.

Puma Biotechnology announces positive financial results for Q4 and full year 2024, with net income increasing due to strong commercial performance and disciplined financial management.

Puma Biotechnology reported a profitable third quarter for 2024, driven by increased product and royalty revenues, and provided an optimistic outlook for the remainder of the year.

Puma Biotechnology, despite a jury win in a patent infringement case against AstraZeneca, has had key patent claims invalidated by the court, leading to an appeal.

Puma Biotechnology's partner, Wyeth, won a jury trial against AstraZeneca for patent infringement, but a judge later ruled key claims of the patents invalid, impacting potential future royalties.

Puma Biotechnology, through its licensee Wyeth, secured a $107.5 million jury award against AstraZeneca for patent infringement related to Tagrisso, with a judge ruling in favor of Wyeth on all remaining claims.

Puma Biotechnology announced its second quarter 2024 financial results, reporting a net loss but highlighting progress in clinical trials for its drug candidates.

Puma Biotechnology's stockholders approved an amendment to the 2011 Incentive Award Plan, increasing the share reserve and extending the option grant period, and elected eight directors at the 2024 Annual Meeting.

Puma Biotechnology's partner, Wyeth, secured a $107.5 million jury verdict against AstraZeneca for patent infringement related to lung cancer treatment drug Tagrisso.

Puma Biotechnology reported a net loss for the first quarter of 2024, despite an increase in cash from operating activities, and provided financial guidance for the rest of the year.

Puma Biotechnology's patent infringement lawsuit against AstraZeneca will proceed to a jury trial after a court ruling on motions, though Puma was dismissed as a plaintiff due to standing issues.

Puma Biotechnology announced positive net income for both the fourth quarter and full year 2023, driven by sales of NERLYNX and increased royalty revenue.

Puma Biotechnology's CEO, Alan H. Auerbach, is scheduled to present at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024.